Society of Urologic Oncology position statement: Redefining the management of hormone‐refractory prostate carcinoma

Chang, Sam S.; Benson, Mitchell C.; Campbell, Steven C.; Crook, Juanita; Dreicer, Robert; Evans, Christopher P.; Hall, M. Craig; Higano, Celestia S.; Kelly, William Kevin; Sartor, Oliver; Smith, Joseph A.

doi:10.1002/cncr.20726

Cited by 32 publications

(16 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ahmad (2004) 91 Commentary/overview Anonymous (2002) 92 Wrong patient group Anonymous (2004) 93 Commentary/overview Anonymous (2001) 94 Background Anonymous (2000) 95 Background Arcenas (2003) 96 Not an RCT Arlen (2002) 97 Commentary/overview Autorino (2003) 98 Commentary/overview Aventis Pharma (2004) 99 Background Aventis Pharma (2004) 100 Background Aventis Pharma (2004) 101 Background Aventis Pharma (2004) 16 Background Beedassy (1999) 102 Commentary/overview Beer (2000) 103 Not an RCT Beer (2003) 104 Background Beer (2002) 105 Background Beer (2004) 106 Background Beer (2001) 107 Background Beitz (1999) 108 Commentary/overview Bernardi (2004) 109 Not an RCT Berry (2003) 110 Not an RCT Bloomfield (1997) 111 Not an RCT Bloomfield (1997) 112 Not an RCT Bosnjak (2003) 113 Background Bracarda (2002) 114 Not an RCT Brandes (2000) 115 Not an RCT Bucher (1997) 63 Background Cancer Research UK (2004) 117 Commentary/overview Carducci (1999) 118 Commentary/overview Centre for Reviews and Dissemination (2001) 23 Background Chamberlain (1997) 11 Background Chang (2005) 119 Background Chatta (2004) 120 Commentary/overview Clarke (2004) 121 Background Coleman (2004) 10 Background Collette (2004) 122 Commentary/overview …”

Section: Study Details Reason For Exclusionmentioning

confidence: 99%

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

Collins¹,

Fenwick²,

Trowman³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for HealthResearch (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as ro...

show abstract

Section: Study Details Reason For Exclusionmentioning

confidence: 99%

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

Collins¹,

Fenwick²,

Trowman³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…There has been no consensus regarding the most appropriate nomenclature for progressive prostate cancer [12]. However, measurable progression of disease despite castrate levels of serum testosterone or progressive disease, as evidenced by at least one new lesion on bone scan or increasing PSA level (minimum 5 ng/ml with two consecutive increases of 50%), has been labelled as either androgen-independent prostate cancer (AIPC), i.e.…”

Section: Discussionmentioning

confidence: 98%

Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer?

Kotwal

Whelan

2008

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

Most patients with a PSA response after primary hormone therapy show a further response to hormones before becoming truly hormone-refractory. There is a concern that the rush to use novel agents will reduce the period of successful palliation in these patients rather than being additive. Patients should show complete hormone refractoriness before newer agents are added to prostate cancer treatment.

show abstract

“…Traditionally, a PSA value of 4.0 ng/ml has been used as the upper limit of normal. The level of the PSA is usually higher in men with prostate cancer than in men without cancer (Chang et al 2005). Cancer cells usually produce more PSA, however also any other conditions that disrupt the normal architecture of the prostate, including nodular hyperplasia, prostatitis, prostatolithiasis, may also cause an elevation in serum levels of PSA (Underwood and Cross 2009).…”

Section: Discussionmentioning

confidence: 99%

The application of the RT-PCR method for the staging of the prostate cancer progression

Zummerova¹,

Labas²,

Böhmer³

et al. 2010

gpb

View full text Add to dashboard Cite

Abstract. Molecular biology seems to bring more convincing markers for the detection of prostate cancer as well as the development of metastases than immunohistochemistry. The main goal of present work was to detect the expression of prostate specific antigen (PSA) and prostate-specific membrane antigen (PSM) genes in the micrometastases by the RT-PCR to assess the progression of prostate cancer. We analyzed 50 patients: 28 patients with clinically localized or locally advanced prostate cancer who underwent radical prostatectomy, 7 patients with clinically proven metastases, 8 patients with benign prostatic hyperplasia, and 7 healthy young men. The results of RT-PCR in the first group of 28 patients varied, however, they were in good correlation with the health status of the patients. Positive results of PSA and notably for PSM were good predictors of beginning metastasing process. Seven patients with metastatic disease had positive RT-PCR results both for PSA and PSM. All of the patients with benign prostatic hyperplasia and healthy young men had negative RT-PCR results for PSA and PSM. The study showed that positive RT-PCR results for PSA and especially for PSM correlated well with the progression of the disease and negative results reflected good health status of the patients.

show abstract

Society of Urologic Oncology position statement: Redefining the management of hormone‐refractory prostate carcinoma

Abstract: Because patients with hormone-refractory prostate carcinoma are a very diverse group, management of these patients represents a unique challenge. Despite much research, to the authors' knowledge few studies published to date have provided

Cited by 32 publications

References 72 publications

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer?

The application of the RT-PCR method for the staging of the prostate cancer progression

Contact Info

Product

Resources

About